34668 Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trials

Abstract

Background: Deucravacitinib is a novel, oral selective inhibitor of TYK2, which mediates signaling of key cytokines in psoriasis pathogenesis. This analysis compared the efficacy of deucravacitinib versus placebo and apremilast in individual scoring components and body regions of PASI.